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Abstract 
 
This report describes the production of ERM®-DA480/IFCC, ERM®-DA481/IFCC and ERM®-DA482/IFCC, which are human cerebrospinal fluid (CSF) materials 
certified for the mass concentration of amyloid β1-42 peptide (Aβ1-42). These materials were produced by the European Commission's Joint Research Centre 
(EC-JRC) in collaboration with the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) following ISO Guide 34:2009 and are 
certified in accordance with ISO Guide 35:2006. 
The starting material used to prepare ERM-DA480/IFCC, ERM-DA481/IFCC and ERM-DA482/IFCC was human CSF collected from normal pressure 
hydrocephalus patients by continuous lumbar drainage. After collection, the CSF was aliquoted and frozen at -80 °C. For the preparation of each certified 
reference material (CRM) a selected number of CSF donations were thawed, pooled, mixed, filled in microvials and stored at (-70 ± 10) °C immediately 
thereafter. 
Between unit-homogeneity was quantified and stability during dispatch and storage were assessed in accordance with ISO Guide 35:2006. 
The material was characterised by an interlaboratory comparison of laboratories of demonstrated competence and adhering to ISO/IEC 17025. Technically 
invalid results were removed but no outlier was eliminated on statistical grounds only. 
Uncertainties of the certified values were calculated in accordance with the Guide to the Expression of Uncertainty in Measurement (GUM) and include 
uncertainties related to possible inhomogeneity, instability and characterisation. 
The materials are intended for the calibration of methods, quality control and/or the assessment of method performance. As with any reference material, 
they can be used for establishing control charts or in validation studies. The CRMs are available in microvials containing at least 0.5 mL of frozen liquid. 
The minimum amount of sample to be used is 15 µL.  
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1 
Summary 
This report describes the production of ERM®-DA480/IFCC, ERM®-DA481/IFCC and     
ERM®-DA482/IFCC, which are human cerebrospinal fluid (CSF) materials certified for the 
mass concentration of amyloid β1-42 peptide (Aβ1-42). These materials were produced by the 
European Commission's Joint Research Centre (EC-JRC) in collaboration with the 
International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) following ISO 
Guide 34:2009 [1] and are certified in accordance with ISO Guide 35:2006 [2]. 
The starting material used to prepare ERM-DA480/IFCC, ERM-DA481/IFCC and ERM-
DA482/IFCC was human CSF collected from normal pressure hydrocephalus patients by 
continuous lumbar drainage. After collection, the CSF was aliquoted and frozen at -80 °C. 
For the preparation of each certified reference material (CRM) a selected number of CSF 
donations were thawed, pooled, mixed, filled in microvials and stored at (-70 ± 10) °C 
immediately thereafter. 
Between unit-homogeneity was quantified and stability during dispatch and storage were 
assessed in accordance with ISO Guide 35:2006 [2]. 
The material was characterised by an interlaboratory comparison of laboratories of 
demonstrated competence and adhering to ISO/IEC 17025 [3]. Technically invalid results 
were removed but no outlier was eliminated on statistical grounds only. 
Uncertainties of the certified values were calculated in accordance with the Guide to the 
Expression of Uncertainty in Measurement (GUM) [4] and include uncertainties related to 
possible inhomogeneity, instability and characterisation. 
The materials are intended for the calibration of methods, quality control and/or the 
assessment of method performance. As with any reference material, they can be used for 
establishing control charts or in validation studies. The CRMs are available in microvials 
containing at least 0.5 mL of frozen liquid. The minimum amount of sample to be used is 
15 µL. 
The following values were assigned: 
 
Amyloid β1-42 peptide in 
human CSF1) 
Mass concentration 
Certified value 2) 
[µg/L] 
Uncertainty 3) 
[µg/L] 
ERM-DA480/IFCC 0.45 0.07 
ERM-DA481/IFCC 0.72 0.11 
ERM-DA482/IFCC 1.22 0.18 
1)
 As obtained by solid phase extraction and subsequent quantification by liquid chromatography with mass spectrometry 
detection, according to the reference methods (Leinenbach et al. Clin. Chem. 60 (2014) 987-94; Korecka et al. J. 
Alzheimers Dis. 41 (2014) 441-451) [5,6]. 
2)
 Certified values are values that fulfil the highest standards of accuracy and represent the unweighted mean value of 
the means of 5 accepted sets of data, each set being obtained in a different laboratory. The certified value and its 
uncertainty are traceable to the International System of Units (SI). 
3)
 The uncertainty is the expanded uncertainty of the certified value with a coverage factor k = 2 corresponding to a 
level of confidence of about 95 % estimated in accordance with ISO/IEC Guide 98-3, Guide to the Expression of 
Uncertainty in Measurement (GUM:1995), ISO, 2008 [4]. 
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Glossary 
Aβ1-42 Amyloid β1-42 peptide 
AAA 
ACN 
AD 
Amino Acid Analysis 
Acetonitrile 
Alzheimer's disease 
ANOVA  Analysis of variance 
BE Belgium 
CRM Certified reference material 
CSF Cerebrospinal fluid 
DE Germany 
DK Denmark 
EC European Commission 
ELISA Enzyme – linked immunosorbent assay 
ERM® Trademark of European Reference Materials 
EU European Union 
g Gravitational acceleration 
GUM Guide to the Expression of Uncertainty in Measurement 
HFIP Hexafluoroisopropanol 
HIV Human immunodeficiency virus 
HPLC-MS High performance liquid chromatography mass spectrometry 
ID  Isotope dilution 
IDMS Isotope dilution mass spectrometry 
IFCC International Federation of Clinical Chemistry and Laboratory Medicine 
ISO International Organization for Standardization  
IVD In Vitro Diagnostics 
IVD-MD In vitro diagnostic medical devices 
JCTLM Joint Committee for Traceability in Laboratory Medicine 
JRC Joint Research Centre of the European Commission 
k Coverage factor 
LC-MS Liquid chromatography-mass spectrometry 
MeOH Methanol 
MS Mass spectrometry 
MSbetween Mean of squares between-unit from an ANOVA 
MSwithin  Mean of squares within-unit from an ANOVA 
n
 
Number of replicates per unit 
5 
N Number of samples (units) analysed 
NH4OH Ammonium hydroxide 
p Number of accepted datasets 
PP Polypropylene 
rel Index denoting relative figures (uncertainties etc.) 
RMPs Reference measurement procedures 
rpm Revolutions per minute 
s Standard deviation 
sbb Between-unit standard deviation; an additional index "rel" is added when 
appropriate 
sbetween
 Standard deviation between groups as obtained from ANOVA; an 
additional index "rel" is added as appropriate 
SE Sweden 
SI International System of Units 
SPE Solid phase extraction 
swithin Standard deviation within groups as obtained from ANOVA; an additional 
index "rel" is added as appropriate 
swb Within-unit standard deviation 
T Temperature 
TFE 
t 
2,2,2,-trifluoroethanol 
Time 
ti Time point for each replicate 
tsl Proposed shelf life 
u Standard uncertainty  
U Expanded uncertainty 
u*bb, rel Relative standard uncertainty related to a maximum between-unit 
inhomogeneity that could be hidden by method repeatability/intermediate 
precision 
ubb Standard uncertainty related to a possible between-unit inhomogeneity;  
an additional index "rel" is added as appropriate 
uc Combined standard uncertainty; an additional index "rel" is added as 
appropriate 
ucal Standard uncertainty of calibration 
uchar  Standard uncertainty of the material characterisation; an additional index 
"rel" is added as appropriate 
uCRM Combined standard uncertainty of the certified value; an additional index 
"rel" is added as appropriate 
UCRM  Expanded uncertainty of the certified value; an additional index "rel" is 
added as appropriate 
ults Standard uncertainty of the long-term stability; an additional index "rel" is 
added as appropriate 
6 
umeas Standard measurement uncertainty 
Umeas Expanded measurement uncertainty 
US United States of America 
usts Standard uncertainty of the short-term stability; an additional index "rel" is 
added as appropriate 
UV Ultraviolet 
V Volume 
WG-CSF (IFCC) Working group for CSF proteins 
x
 
Arithmetic mean 
∆meas Absolute difference between mean measured value and the certified value 
νs,meas Degrees of freedom for the determination of the standard deviation smeas 
MSwithinν
 
Degrees of freedom of MSwithin 
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1 Introduction  
1.1 Background 
The early diagnosis and treatment of Alzheimer's disease (AD) remain challenging and the 
use of biomarkers like the Aβ1-42 peptide could contribute to improve early diagnosis. 
However, analysis results from different routine measurement procedures show large 
variability for this biomarker. 
In 2011 a working group for cerebrospinal fluid (CSF) proteins (WG-CSF) was created by the 
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), with the 
purpose of developing certified reference materials (CRMs) and reference measurement 
procedures (RMPs) for international use. The WG-CSF decided to first focus on Aβ1-42 as a 
biomarker for AD. After a commutability study including immunoassays for Aβ1-42 from 
different manufacturers and a ring trial using different liquid chromatography-mass 
spectrometry (LC-MS) methods among four laboratories showed promising results, the JRC 
committed to the production of a CRM for Aβ1-42 in human CSF. In the meantime, two 
reference measurement procedures using selected reaction monitoring LC-MS for 
quantification of Aβ1-42 in human CSF were developed [5, 6] and subsequently listed by the 
Joint Committee for Traceability in Laboratory Medicine (JCTLM). 
The EU Directive on in vitro diagnostic medical devices (IVD-MD) (Directive 98/79/EC) 
requires traceability of calibrants and control materials to reference measurement procedures 
and/or reference materials of higher order. 
A CRM is required to have an assigned value that is metrologically traceable, and 
accompanied by an uncertainty statement. The stability and homogeneity with respect to the 
certified property must be verified. 
In collaboration with the IFCC WG-CSF, the JRC produced three CRMs certified for the 
mass concentration of Aβ1-42 in CSF. The materials, ERM-DA480/IFCC, ERM-DA481/IFCC, 
ERM-DA482/IFCC, are intended to be used as calibrators or quality control materials for 
methods for the measurement of Aβ1-42 in CSF. The homogeneity and the stability of the 
CRMs were demonstrated and the certified value was assigned using the reference 
measurement procedures in an interlaboratory comparison among expert laboratories. The 
commutability of the CRMs was assessed in a study including six routine measurement 
procedures. 
1.2 Choice of the material 
Human CSF was chosen as the starting material for the CRM because artificial matrices 
were found not to be commutable for the methods tested in a first commutability study [7]. 
Furthermore, three concentration levels were produced to allow users to prepare calibration 
curves. A frozen liquid material was selected as it had displayed suitable stability in previous 
studies [8]. 
1.3 Design of the CRM project 
Human CSF was collected from normal pressure hydrocephalus patients by continuous 
lumbar drainage, aliquoted and frozen at -80 °C. For the preparation of the certified reference 
material a selected number of CSF donations were thawed and combined in order to 
produce three materials with high, middle and low levels of Aβ1-42.  
For each mass concentration level, batches of 0.5 mL aliquots were prepared and stored 
frozen at -70 °C. 
8 
Based on the outcome of several processing feasibility studies and the known fact that Aβ1-42 
is very prone to adhesion to surfaces, assessment of the homogeneity of the processed 
material was crucial. 
After verification of the suitable homogeneity of ERM-DA481/IFCC the other two materials 
were processed using the same processing technique. 
The CRMs were characterised by liquid chromatography with mass spectrometry detection 
(LC-MS) using reference measurement procedures [5, 6]. The measurements were 
performed by expert laboratories that have previously shown their proficiency in a ring trial. 
The LC-MS measurements were calibrated using calibrators prepared from a common stock 
solution of Aβ1-42. The calibrants were prepared, aliquoted and characterised by the JRC. 
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2 Participants 
2.1 Project management and evaluation 
European Commission, Joint Research Centre (JRC), Geel, BE (accredited to ISO Guide 34 for 
production of certified reference materials, BELAC No. 268-RM) 
2.2 Provision of raw materials 
The Sahlgrenska Academy, University of Gothenburg, Mölndal, SE (accredited to ISO 15189, 
Swedish Board for Accreditation and Conformity Assessment, No. 1240) 
2.3 Processing  
European Commission, Joint Research Centre (JRC), Geel, BE (accredited to ISO Guide 34 for 
production of certified reference materials, BELAC No. 268-RM) 
2.4 Homogeneity study 
Roche Diagnostics GmbH, Penzberg, DE  
ADx NeuroSciences NV, Gent, BE  
2.5 Stability study 
European Commission, Joint Research Centre (JRC), Geel, BE (accredited to ISO Guide 34 for 
production of certified reference materials, BELAC No. 268-RM) 
ADx NeuroSciences NV, Gent, BE  
2.6 Characterisation 
European Commission, Joint Research Centre (JRC), Geel, BE  
PPD Laboratories, Richmond, VA, US 
Roche Diagnostics GmbH, Penzberg, DE  
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US  
The Sahlgrenska Academy, University of Gothenburg, Mölndal, SE (accredited to ISO 15189, 
Swedish Board for Accreditation and Conformity Assessment, No. 1240) 
Waters Corporation, Milford, MA, US 
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3 Material processing and process control 
3.1 Origin of the starting material 
The raw material was human CSF provided by Sahlgrenska Academy at University of 
Gothenburg (Mölndal, SE). The CSF was collected from normal pressure hydrocephalus 
patients by continuous lumbar drainage from a catheter in a plastic bag over several hours at 
room temperature. After collection, the CSF was aliquoted into 50 mL polypropylene (PP) 
tubes and frozen individually at the Swedish neurological clinics where it was collected. The 
anonymised CSF donations were then sent on dry ice to the Salgrenska Academy at the 
University of Gothenburg where the Aβ1-42 concentration of each donation was determined by 
ELISA (INNOTEST® Amyloid β(1-42), Fujirebio Europe N.V., Gent, Belgium). Each individual 
CSF donation was tested for anti-HIV1/HIV2 antibodies and found to be negative. Since the 
donors were under continuous medical surveillance, there is no particular risk that this donor 
population should have had any bacterial or viral infections of the central nervous system at 
the time of CSF collection. 
3.2 Processing 
For the processing of each CRM, a selected number of CSF donations were removed from 
the freezer and thawed in a water bath at room temperature. Based on the Aβ1-42 
concentrations of each of the individual donations, the three materials were produced by 
pooling together different donations with high, middle and low levels of Aβ1-42. The pooling 
was done in three autoclaved 2 litre PP beakers and the CSF pools were stirred, using a 6 
cm magnetic stir bar, for one hour at room temperature and 200 rpm. Each CSF pool was 
then divided between two autoclaved PP centrifuge bottles and centrifuged for ten minutes at 
2000 x g at room temperature. The supernatant was transferred to a clean, autoclaved PP 
bottle (4 litre bottle for ERM-DA480/IFCC and ERM-DA482/IFCC and 2 litre bottle for ERM-
DA481/IFCC) and stirred, using a 6 cm magnetic stir bar, for one hour at 200 rpm and room 
temperature. Then it was transferred to a cold room (4 ± 3 °C) where it remained overnight 
until further processing. 
The CSF pools, were filled in 0.5 mL sterile microvials SCT-050-SS-L-X-S (where X depends 
on the cap colour) maximum recovery (Axygen Scientific, Inc., Union City, CA, USA) and 
closed with screw caps with O-rings using a filling machine (Dencore ApS, Jyllinge, DK) 
placed under a clean cell (Terra Universal, Inc., Fullerton, CA, USA). The CSF pool was 
stirred and kept on ice during filling. Each vial was filled with at least 0.5 mL of CSF. The 
vials were stored at (-70 ± 10) °C immediately after filling and labelling. 
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4 Homogeneity 
A key requirement for any reference material aliquoted into units is equivalence between 
those units. In this respect, it is relevant whether the variation between units is significant 
compared to the uncertainty of the certified value, but it is not relevant if this variation 
between units is significant compared to the analytical variation. Consequently, ISO Guide 34 
[1] requires reference material producers to quantify the between unit variation. This aspect 
is covered in between-unit homogeneity studies. 
The within-unit inhomogeneity does not influence the uncertainty of the certified value when 
the minimum sample intake is respected, but determines the minimum size of an aliquot that 
is representative for the whole unit. 
4.1 Between-unit homogeneity 
The between-unit homogeneity was evaluated to ensure that the certified values of the 
CRMs are valid for all vials of the material, within the stated uncertainties. 
The number of vials selected corresponds to at least the cube root of the total number of 
vials produced. Seventy vials were selected for ERM-DA481/IFCC and 35 vials for 
ERM-DA480/IFCC and ERM-DA482/IFCC using a random stratified sampling scheme 
covering the whole batch for the between-unit homogeneity test. For this, the batch for 
ERM-DA481/IFCC was divided into 70 and the other two batches were divided into 35 
groups (with a similar number of vials) and one vial was selected randomly from each group. 
Three independent samples were taken from each selected vial and analysed with a fully 
automated immunoassay (Roche Elecsys β-amyloid (1-42), Roche Diagnostics GmbH, 
Penzberg, DE). In addition to that, another 70 vials of ERM-DA481/IFCC and 35 vials of 
ERM-AD480/IFCC as well as ERM-DA482/IFCC were selected and analysed in the same 
manner to assess the homogeneity of Aβ1-42 with a manual ELISA (EUROIMMUN beta-
amyloid (1-42), EUROIMMUN AG, Lübeck, DE). Except for the measurements of ERM-
DA481/IFCC using the automated analyser, all the measurements were performed under 
repeatability conditions, and in a randomised manner to be able to separate a potential 
analytical drift from a trend in the filling sequence. 
Regression analyses were performed to evaluate potential trends in the analytical sequence 
as well as trends in the filling sequence. No trends in the filling sequence were observed at a 
95 % confidence level, besides a trend for ERM-DA481/IFCC analysed with the fully 
automated immunoassay. For this last material it was confirmed with the EUROIMMUN 
ELISA that there was no trend in the filling sequence. Significant (95 % confidence level) 
trends in the analytical sequence were visible for both methods. The correction of biases, 
even if they are statistically not significant, was found to combine the smallest uncertainty 
with the highest probability to cover the true value [9]. Correction of trends is therefore 
expected to improve the sensitivity of the subsequent statistical analysis through a reduction 
in analytical variation without masking potential between-unit heterogeneities. As the 
analytical sequence and the unit numbers were not correlated, trends significant on at least a 
95 % confidence level were corrected as shown below. The systematic decrease of Aβ1-42 
seen for the results of the fully automated immunoassay were corrected as shown in 
Equation 1 and the interplate variability of the ELISA was corrected as shown in Equation 2. 
12 
 
ireplicate
replicatei
corri
x
xx
x
_
1_
_
⋅
=
 Equation 1 
ix = individual result within the run  
1replicate_x  = average of results replicate run 1 
ireplicate_x  = average of results replicate run with individual result i 
 
plate
platesalli
corri
x
xx
x
_
_
⋅
=
 Equation 2 
ix = individual result on the plate 
all_platesx  = average of results of all plates 
platex  = average of results of the plate with result i 
The trend-corrected datasets were assessed for consistency using Grubbs outlier tests at a 
confidence level of 99 % on the individual results and on the unit means. No outlying 
individual results or outlying unit means were detected. 
Quantification of between-unit inhomogeneity was undertaken by analysis of variance 
(ANOVA), which separates the between-unit variation (sbb) from the within-unit variation (swb). 
The latter is equivalent to the method repeatability if the individual samples were 
representative for the whole vial. 
Evaluation by ANOVA requires mean values per vial, which follow at least a unimodal 
distribution and results for each vial that follow unimodal distributions with approximately the 
same standard deviations. Too few data are available for the unit means to make a clear 
statement of the distribution based on statistical tests. Therefore, it was checked visually 
whether all individual data follow a unimodal distribution using histograms and normal 
probability plots. Minor deviations from unimodality of the individual values do not 
significantly affect the estimate of between-unit standard deviations. The results of all 
statistical evaluations are given in Table 1 and 2. 
 
Table 1: Results of the statistical evaluation of the homogeneity studies of Aβ1-42 using a 
fully automated immunoassay (Roche Elecsys β-amyloid (1-42), Roche Diagnostics 
GmbH) 
Aβ1-42 
Trends 
(before correction)* Outliers** Distribution 
Analytical 
sequence 
Filling 
sequence 
Individual 
results 
Unit 
means 
Individual 
results 
Unit 
means 
ERM-
DA480/IFCC yes no none none unimodal unimodal 
ERM-
DA481/IFCC yes yes none none unimodal unimodal 
ERM-
DA482/IFCC yes no none none unimodal unimodal 
*  95 % confidence level 
** 99 % confidence level 
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Table 2: Results of the statistical evaluation of the homogeneity studies of Aβ1-42 using an 
ELISA (EUROIMMUN beta-amyloid (1-42), EUROIMMUN AG) 
Aβ1-42 
Trends 
(before correction)* Outliers** Distribution 
Analytical 
sequence 
Filling 
sequence 
Individual 
results 
Unit 
means 
Individual 
results 
Unit 
means 
ERM-
DA480/IFCC yes no none none unimodal unimodal 
ERM-
DA481/IFCC no no none none unimodal unimodal 
ERM-
DA482/IFCC yes no none none unimodal unimodal 
*  95 % confidence level 
** 99 % confidence level 
 
Method repeatability (swb,rel), between-unit standard deviation (sbb,rel) and u*bb,rel were 
calculated as: 
x ,
within
relwb
MS
s =
 Equation 3 
x
n
MSMS
s
withinbetween
relbb
−
=
,
 Equation 4 
x
νn
MS
u MSwithin
within
*
relbb
4
,
2
=  Equation 5 
 
MSwithin mean of squares within-unit from an ANOVA  
MSbetween mean of squares between-unit from an ANOVA 
x  mean of all results of the homogeneity study 
n mean number of replicates per unit 
MSwithinν  degrees of freedom of MSwithin  
 
It should be noted that sbb,rel and swb,rel are estimates of the true standard deviations and are 
therefore subject to random fluctuations. Therefore, the mean square between groups 
(MSbetween) can be smaller than the mean squares within groups (MSwithin), resulting in 
negative arguments under the square root used for the estimation of the between-unit 
variation, whereas the true variation cannot be lower than zero. In this case, u*bb, the 
maximum inhomogeneity that could be hidden by method repeatability, was calculated as 
described by Linsinger et al. [10]. u*bb is comparable to the limit of detection of an analytical 
method, yielding the maximum inhomogeneity that might be undetected by the given study 
setup. 
 
The results of the evaluation of the between-unit variation are summarised in Table 3 and 4. 
The resulting values from the above equations were converted into relative uncertainties.  
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Table 3: Results of the homogeneity studies of Aβ1-42 using a fully automated 
immunoassay 
Aβ1-42 in CSF swb,rel [%] sbb,rel [%] u*bb,rel [%] ubb, rel [%] 
ERM-DA480/IFCC 1.7 2.0 0.4 2.0 
ERM-DA481/IFCC 3.5 1.1 0.7 1.1 
ERM-DA482/IFCC 1.5 1.1 0.4 1.1 
 
Table 4: Results of the homogeneity studies of Aβ1-42 using an ELISA 
Aβ1-42 in CSF swb,rel [%] sbb,rel [%] u*bb,rel [%] ubb, rel [%] 
ERM-DA480/IFCC 5.1 1.3 1.2 1.3 
ERM-DA481/IFCC 5.1 1.3 1.0 1.3 
ERM-DA482/IFCC 5.2 1.5 1.2 1.5 
 
The homogeneity study showed no outlying unit means or trends in the filling sequence. 
Therefore, the between-unit standard deviation can be used as estimate of ubb. As u*bb sets 
the limits of the study to detect inhomogeneity, the larger value of sbb and u*bb is adopted as 
uncertainty contribution to account for potential inhomogeneity. 
4.2 Within-unit homogeneity and minimum sample intake 
The within-unit homogeneity is closely correlated to the minimum sample intake. The 
minimum sample intake is the minimum amount of sample that is representative for the 
whole unit and thus should be used in an analysis. Using sample sizes equal or above the 
minimum sample intake guarantees the certified value within its stated uncertainty.  
Homogeneity and stability experiments were performed using a 15 µL sample intake. This 
sample intake gives acceptable repeatability, demonstrating that the within-unit 
inhomogeneity no longer contributes to analytical variation at this sample intake. 
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5 Stability 
Time and temperature were regarded as the most relevant influences on the stability of the 
materials. The influence of ultraviolet or visible light was minimised by storing the material in 
the dark and dispatching in boxes, thus removing any possibility of degradation by light. 
Therefore, only the influences of time and temperature needed to be investigated. 
Stability testing is necessary to establish the conditions for storage (long-term stability) as 
well as the conditions for dispatch of the materials to the customers (short-term stability). 
During transport, especially in summer time, temperatures up to 60 °C can be reached and 
stability under these conditions must be demonstrated, if the samples are to be transported 
without any additional cooling. 
The stability studies were carried out using an isochronous design [11]. In this approach, 
samples were stored for a particular length of time at different temperature conditions. 
Afterwards, the samples were moved to conditions where further degradation can be 
assumed to be negligible (reference conditions). At the end of the isochronous storage, the 
samples were analysed simultaneously under repeatability conditions. Analysis of the 
material (after various exposure times and temperatures) under repeatability conditions 
greatly improves the sensitivity of the stability tests. 
5.1 Short-term stability study 
For the short-term stability study, samples were stored at -70 °C, -20 °C, 4 °C and 18 °C for 
0, 1, 2 and 4 weeks (at each temperature). The reference temperature was set to -150 °C 
(stored above liquid nitrogen). Two vials per storage time were selected using a random 
stratified sampling scheme. From each vial, three samples were measured by ELISA 
(EUROIMMUN beta-amyloid (1-42), EUROIMMUN AG, Lübeck, DE). The measurements 
were performed under repeatability conditions, and a randomised sequence was used to 
differentiate any potential analytical drift from a trend over storage time. 
The data were evaluated individually for each temperature. The results were screened for 
outliers using the single and double Grubbs test on a confidence level of 99 %. No outlying 
individual results were found (Table 5). 
In addition, the data were evaluated against storage time, and regression lines of mass 
concentration versus time were calculated, to test for potential increases/decrease of Aβ1-42 
mass concentration due to shipping conditions. The slopes of the regression lines were 
tested for statistical significance. None of the trends was statistically significant at a 95 % 
confidence level for -20 °C (these results are shown in Annex B), but some trends were 
detected at the other temperatures tested. The results of the statistical evaluation of the 
short-term stability are summarised in Table 5. 
 
Table 5: Results of the short-term stability tests 
Aβ1-42 in CSF 
Number of individual outlying results* Significance of the trend** 
-70 ºC -20 ºC 4 °C 18 °C -70 ºC -20 ºC 4 °C 18 °C 
ERM-DA480/IFCC none none none none yes no no yes 
ERM-DA481/IFCC none none none none no no yes yes 
ERM-DA482/IFCC none none none none no no no yes 
*  99 % confidence level 
** 95 % confidence level 
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No statistical outliers were detected for the analyte (99 % confidence level), and all the 
samples were retained for the estimation of usts. 
A significant trend at -70 °C was found for ERM-DA480/IFCC, but since the long-term 
stability study results at -70 °C did not show a trend, the observation in the short-term 
stability study was regarded as a statistical artefact. Furthermore, no statistically significant 
trend was found for ERM-DA481/IFCC or ERM-DA482/IFCC at -70 °C or -20 °C. A significant 
trend at 4 °C was found for ERM-DA481/IFCC, but not for ERM-DA480/IFCC and ERM-
DA482/IFCC. A significant trend at 18 °C was found for all three materials. 
The material shall be shipped on dry ice to avoid freeze-thaw cycles. 
5.2 Long-term stability study 
For the long-term stability study, samples were stored at -70 °C and -20 °C for 0, 4, 8 and 12 
months (at each temperature). The reference temperature was set to -150 °C (stored above 
liquid nitrogen). Two samples per storage time were selected using a random stratified 
sampling scheme. From each vial, three samples were measured by ELISA (EUROIMMUN 
beta-amyloid (1-42), EUROIMMUN AG, Lübeck, DE). The measurements were performed 
under repeatability conditions in a random sequence to be able to separate any potential 
analytical drift from a trend over storage time. For ERM-DA480/IFCC, one value was 
removed for technical reasons.  
The long-term stability data were evaluated individually for each temperature. The results 
were screened for outliers using the single and double Grubbs test at a confidence level of 
99 %. One outlying individual result was found for ERM-DA482/IFCC (Table 6). As no 
technical reason for the outlier could be found, all data were retained for statistical analysis.  
In addition, the data were plotted against storage time and linear regression lines of mass 
concentration versus time were calculated. The slopes of the regression lines were tested for 
statistical significance (loss/increase due to storage). No significant trend was detected at a 
95 % confidence level. 
The results of the long-term stability measurements at -70 °C are shown in Annex C. The 
results of the statistical evaluation of the long-term stability study are summarised in Table 6.  
 
Table 6: Results of the long-term stability tests 
Aβ1-42 in CSF 
Number of individual outlying results* Significance of the trend** 
-70 °C -20 °C -70 °C -20 °C 
ERM-DA480/IFCC none none no no 
ERM-DA481/IFCC none none no no 
ERM-DA482/IFCC none 1 no no 
*  99 % confidence level 
** 95 % confidence level 
 
None of the trends was statistically significant on a 99 % confidence level for any of the 
temperatures. The material can therefore be stored at -70 °C. 
5.3 Estimation of uncertainties 
Due to the intrinsic variation of measurement results, no study can entirely rule out 
degradation of materials, even in the absence of statistically significant trends. It is therefore 
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necessary to quantify the potential degradation that could be hidden by the method 
repeatability, i.e. to estimate the uncertainty of stability. This means that, even under ideal 
conditions, the outcome of a stability study can only be that there is no detectable 
degradation within an uncertainty to be estimated. 
The uncertainties of stability during dispatch and storage were estimated as described in 
[12]. In this approach, the uncertainty of the linear regression line with a slope of zero was 
calculated. The uncertainty contributions usts and ults were calculated as the product of the 
chosen transport time/shelf life and the uncertainty of the regression lines as: 
( ) tti
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 Equation 7 
srel  relative standard deviation of all results of the stability study 
ti time elapsed at time point i 
t  mean of all ti 
ttt chosen transport time (1 week at -20 ºC) 
tsl chosen shelf life (12 months at -70 ºC) 
 
The following uncertainties were estimated: 
- usts,rel, the uncertainty of degradation during dispatch. This was estimated from the  
-20 °C studies. The uncertainty describes the possible change during a dispatch at  
-20 °C lasting for one week. 
- ults,rel, the stability during storage. This uncertainty contribution was estimated from the 
-70 °C study. The uncertainty contribution describes the possible degradation during 
12 months storage at -70 °C. 
The results of these evaluations are summarised in Table 7. 
 
Table 7: Uncertainties of stability during dispatch and storage. usts,rel was calculated for 
a temperature of -20 °C and 1 week; ults,rel was calculated for a storage temperature of  
-70 °C and 12 months 
Aβ1-42 in CSF usts,rel [%] ults,rel [%] 
ERM-DA480/IFCC 0.7 3.0 
ERM-DA481/IFCC 0.8 3.7 
ERM-DA482/IFCC 0.6 3.1 
 
Although two of the three materials did not show a significant degradation at 4 °C, transport 
on dry-ice is necessary. Freeze-thaw cycles should be avoided. 
After the certification study, the materials will be included in the JRC's regular stability 
monitoring programme, to verify its further stability. 
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6 Characterisation 
The material characterisation is the process of determining the property value of a reference 
material. 
This was based on an interlaboratory comparison of expert laboratories, i.e. the mass 
concentration of each of the three materials was determined in different laboratories that 
applied different measurement procedures to demonstrate the absence of a measurement 
bias. Due to the nature of the analyte however, all participants used the same pre-analytical 
sample preparation method for the measurements. This approach aims at randomisation of 
laboratory bias, which reduces the combined uncertainty. 
6.1 Calibration 
6.1.1 Preparation of a Aβ1-42 stock solution  
Preparation of the Aβ1-42 stock solution was based on a procedure adapted from Broersen et 
al. [13]. Recombinant human Aβ1-42 peptides were purchased in form of lyophilised 
hexafluoroisopropanol (HFIP) films (rPeptide, Bogart, GA, USA) with a purity stated to be 
≥97 %. The peptides were dissolved in HFIP (VWR International LLC, Leuven, BE) at a 
concentration of 1 mg/mL, vortex mixed for 30 seconds and dried with argon. Then the 
peptides were dissolved in dimethyl sulfoxide (G-Biosciences, St. Louis, MO, USA) at a 
concentration of 1 mg/mL and vortex mixed for 30 seconds. The peptide solution was 
injected on a HiTrap desalting column (GE Healthcare Europe GmbH, Diegem, BE) 
equilibrated with 20 % acetonitrile and 1 % ammonium hydroxide in water. Fractions were 
collected, pooled and diluted with 20 % acetonitrile and 1 % ammonium hydroxide. The 
peptide solution was filled in 0.5 mL PP vials (Sarstedt, Nümbrecht, DE) with each vial 
containing 0.1 mL of solution. The vials were immediately stored at (-70 ± 10) °C. 
6.1.2 Value assignment of the stock solution 
The value assignment of the stock solution was performed by IDMS using a TSQ Vantage 
MS (Themo Fisher Scientific, Waltham, MA, US), with SPE and LC conditions according to 
the reference measurement procedure [5, 6]. Six different Aβ1-42 preparations were used for 
calibration of these measurements, producing six datasets for the stock solution. The values 
of these six aforementioned Aβ1-42 preparations were determined by amino acid analysis [14]. 
The value for the stock solution (the mean of means of the six datasets) was converted from 
mass fraction to mass concentration using the density of the stock solution. This density was 
determined using a DMA 4500M Density Meter (Anton Paar, Graz, AT), and found to be 
0.9641 g/cm3, with an expanded uncertainty (k = 2) of 0.0001 g/cm3 (based on repeatability 
only) which corresponds to an expanded relative uncertainty of 0.01 %. 
The resulting mass concentration for the stock solution is given in Table 8. 
 
Table 8: Assigned value and uncertainty of the Aβ1-42 concentration in the pure peptide 
solution 
Assigned value [mg/L] ucal,rel [%] 
68.87 3.54 
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6.2 Selection of participants 
Five laboratories were selected based on criteria that comprised both technical competence 
and quality management aspects. Each participant was required to operate a quality system 
and to deliver documented evidence of its laboratory proficiency in the field of Aβ1-42 
measurements in human CSF by submitting results from proficiency testing. Having a formal 
accreditation was not mandatory, but meeting the requirements of ISO/IEC 17025 was 
obligatory. Where measurements are covered by the scope of accreditation, the accreditation 
number is stated in the list of participants (Section 2). 
6.3 Study setup 
Each laboratory received nine vials each of ERM-DA480/IFCC, ERM-DA481/IFCC and ERM-
DA482/IFCC and was requested to provide 27 independent results per CRM, three per vial. 
The units for material characterisation were selected using a random stratified sampling 
scheme and covered the whole batch. The sample preparations and measurements had to 
be spread over at least three days to ensure intermediate precision conditions. Each 
laboratory also received six vials of Aβ1-42 stock solution to perform an independent 
calibration for each day of analysis. 
6.4 Methods used 
The participating laboratories were using validated procedures (Annex D) that were based on 
the IFCC reference measurement procedures for the quantification of Aβ1-42 in CSF [5, 6]. 
6.5 Evaluation of results 
The characterisation study resulted in 5 datasets per material. All individual results of the 
participants are displayed in a graphical form in Annex E. 
6.5.1 Technical evaluation 
The obtained data were first checked for compliance with the requested analysis protocol 
and for their validity based on technical reasons. The following criteria were considered 
during the evaluation: 
- appropriate validation of the measurement procedure 
- compliance with the analysis protocol: sample preparations and measurements 
performed on three days 
During this characterisation study all the data sets were retained. 
6.5.2 Statistical evaluation 
The datasets accepted based on technical reasons were tested for normality of dataset 
means using kurtosis/skewness tests and normal probability plots and were tested for 
outlying means using the Grubbs test and using the Cochran test for outlying standard 
deviations, (both at a 99 % confidence level). Standard deviations within (swithin) and between 
(sbetween) laboratories were calculated using one-way ANOVA. The results of these 
evaluations are shown in Table 9. 
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Table 9: Statistical evaluation of the technically accepted datasets for each CRM.       
p: number of technically valid datasets 
Aβ1-42 in CSF p 
Outliers Normally 
distributed 
Statistical parameters 
Means Variances Mean [µg/L] 
s 
[µg/L] 
sbetween 
[µg/L] 
swithin 
[µg/L] 
ERM-
DA480/IFCC 5 none none yes 0.45 0.05 0.08 0.07 
ERM-
DA481/IFCC 5 1 1 yes 0.72 0.08 0.12 0.12 
ERM-
DA482/IFCC 5 1 1 yes 1.22 0.15 0.24 0.20 
 
For ERM-DA480/IFCC, the laboratory means follow normal distributions. None of the data 
contains outlying means and variances. The datasets are therefore consistent and the mean 
of laboratory means is a good estimate of the true value. Standard deviations between 
laboratories are considerably larger than the standard deviation within laboratories, showing 
that confidence intervals of replicate measurements are unsuitable as estimate of 
measurement uncertainty. 
For ERM-DA481/IFCC and for ERM-DA482/IFCC, the statistical evaluation flags laboratory 
L5 as outlier for the laboratory mean. However, it must be borne in mind that outlier tests do 
not take uncertainty information into consideration. A closer investigation revealed that the 
difference between the mean value of laboratory L5 and the other results is covered by the 
measurement uncertainty of laboratory L5. There is therefore no evidence that the results of 
laboratory L5 deviate from the other results.  
For ERM-DA481/IFCC and for ERM-DA482/IFCC, statistical evaluation flags laboratory L3 
as outlying variance. All laboratories used SPE followed by HPLC-MS, but laboratory L3 only 
had 2 replicates per sample. As all measurement data sets were found technically sound, all 
results were retained. 
The uncertainty related to the characterisation was based on the standard error of the mean 
of laboratory means (Table 10). 
 
Table 10: Uncertainty of characterisation 
Aβ1-42 in CSF p Mean [µg/L] 
s 
[µg/L] 
uchar,rel 
[%] 
ERM-DA480/IFCC 5 0.45 0.05 5.0 
ERM-DA481/IFCC 5 0.72 0.08 5.1 
ERM-DA482/IFCC 5 1.22 0.15 5.6 
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7 Value Assignment 
Certified values were assigned. 
Certified values are values that fulfil the highest standards of accuracy. Full uncertainty 
budgets in accordance with the 'Guide to the Expression of Uncertainty in Measurement' [4] 
were established. 
7.1 Certified values and their uncertainties 
The unweighted mean of the means of the accepted datasets as shown in Table 9 was 
assigned as certified value for each parameter. 
The assigned uncertainty consists of uncertainties relating to characterisation, uchar and to the 
calibrant used ucal (Section 6), potential between-unit inhomogeneity, ubb (Section 4.1), and 
potential degradation during transport, usts, and long-term storage, ults (Section 5). These 
different contributions were combined to estimate the relative expanded uncertainty of the 
certified value (UCRM, rel) with a coverage factor k given as:  
2
rel char,
2
rel lts,
2
rel sts,
2
rel cal,
2
rel bb,rel CRM, uuuuukU ++++⋅=  Equation 8 
- uchar was estimated as described in Section 6 
- ucal is the relative standard uncertainty on the pure peptide solution as described in 
Section 6 
- ubb was estimated as described in Section 4.1. For ERM-DA480/IFCC, ubb was taken 
from the homogeneity study performed by ELISA and for ERM-DA481/IFCC and ERM-
DA482/IFCC from the homogeneity study performed by the fully automated 
immunoassay. 
- usts and ults were estimated as described in Section 5.3 
 
The relevant number of degrees of freedom calculated using the Welch-Satterthwaite 
equation is larger than 30 for any of the three materials which justifies the use of a coverage 
factor k = 2 to expand the confidence level to about 95 %. After rounding, the certified values 
and their uncertainties are summarised in Table 11. 
 
Table 11: Certified values and their uncertainties for ERM-DA480/IFCC, ERM-
DA481/IFCC and ERM-DA482/IFCC 
Aβ1-42 in CSF 
Certified 
value 
[µg/L] 
uchar,rel 
[%]
 
ucal,rel  
[%] 
ubb,rel  
[%]
 
usts,rel  
[%]
 
ults,rel  
[%]
 
UCRM 1) 
[µg/L] 
ERM-
DA480/IFCC 0.45 5.0 3.5 1.3 0.7 3.0 0.07 
ERM-
DA481/IFCC 0.72 5.1 3.5 1.1 0.8 3.7 0.11 
ERM-
DA482/IFCC 1.22 5.6 3.5 1.1 0.6 3.1 0.18 
1)
 Expanded (k = 2) and rounded uncertainty. 
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8 Metrological traceability and commutability 
8.1 Metrological traceability  
Identity 
The Aβ1-42 peptide is a chemically clearly defined substance. However, the characterisation 
of the matrix materials ERM-DA480/IFCC, ERM-DA481/IFCC and ERM-DA482/IFCC was 
performed by using SPE, Liquid Chromatography and Mass Spectrometry (LC-MS) methods 
and therefore the measurand is defined as Aβ1-42 peptide as prepared by SPE and measured 
by LC-MS methods used in the present procedure. 
Quantity value 
Only validated methods were used for the determination of the assigned values. The 
property value assigned to the common calibrant is traceable to the SI, as described in this 
report, and all relevant input parameters were calibrated. The individual results are therefore 
traceable to the SI, as it is also confirmed by the agreement among the technically accepted 
datasets. As the assigned values are combinations of agreeing results individually traceable 
to the SI, the assigned quantity values themselves are traceable to the SI as well. 
8.2 Commutability 
Many measurement procedures include one or more steps which select specific (or specific 
groups of) analytes from the sample for the subsequent whole measurement process. Often 
the complete identity of these 'intermediate analytes' is not fully known or taken into account. 
Therefore, it is difficult to mimic all analytically relevant properties of real samples within a 
CRM. The degree of equivalence in the analytical behaviour of real samples and a CRM with 
respect to various measurement procedures (methods) is summarised in a concept called 
'commutability of a reference material'. There are various definitions that define this concept. 
For instance, the Clinical and Laboratory Standards Institute Guideline EP30-A [15] 
recommends the use of the following definition for the term commutability: 
"A property of a reference material, demonstrated by the equivalence of the mathematical 
relationships among the results of different measurement procedures for a reference 
material and for representative samples of the type intended to be measured." 
The commutability of a CRM defines its fitness for use and is therefore a crucial 
characteristic when applying different measurement methods. When the commutability of a 
CRM is not established, the results from routinely used methods cannot be legitimately 
compared with the certified value to determine whether a bias does not exist in calibration, 
nor can the CRM be used as a calibrant. For instance, CRMs intended to be used to 
establish or verify metrological traceability of results obtained by routine clinical 
measurement procedures must be commutable for the routine clinical measurement 
procedures for which they are intended to be used. 
The individual patient donations were pooled and tested in a commutability study before they 
were processed into the CRMs. The outcome of that study has been published elsewhere 
[7]. After processing, ERM-DA480/IFCC, ERM-DA481/IFCC and ERM-DA482/IFCC were 
tested in another commutability study and shown to be commutable for the combination of 
the following routine measurement procedures:  
- EUROIMMUN beta-amyloid (1-42) (EUROIMMUN AG, Lübeck, DE)  
- IBL Amyloid-beta (1-42) CSF ELISA (IBL International GmbH, Hamburg, DE)  
- INNOTEST® β-AMYLOID (1-42) (Fujirebio Europe, N.V., Gent, BE)  
- Lumipulse® G β-Amyloid (1-42) (Fujirebio Europe N.V., Gent, BE)  
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- V-PLEX® Aβ Peptide Panel 1 (6E10) (Meso Scale Discovery, LLC., Rockville, MD, US) 
- Roche Elecsys β-amyloid (1-42) (Roche Diagnostics GmbH, Penzberg, DE)  
If ERM-DA480/IFCC, ERM-DA481/IFCC and ERM-DA482/IFCC are used for the calibration 
of other Aβ1-42 measurement procedures, the user should verify that the materials or their 
dilutions used are commutable (Annex F). 
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9 Instructions for use 
9.1 Safety information 
The usual laboratory safety measures apply. Do not discharge the waste into the drain. Each 
individual CSF donation was tested for anti-HIV1/HIV2 antibodies and found to be negative. 
Since the donors were under continuous medical surveillance, there is no particular risk that 
this donor population should have had any bacterial or viral infections of the central nervous 
system at the time of CSF collection. However, the product must be handled with adequate 
care as any material of human origin. It is intended for in vitro use only. 
9.2 Storage conditions 
The materials should be stored at -70 ± 10 °C in the dark. 
Please note that the European Commission cannot be held responsible for changes that happen 
during storage of the material at the customer's premises, especially for opened vials. 
9.3 Preparation and use of the material 
The vials shall be thawed at room temperature. Avoid vortexing or inverting the vial in order 
to prevent contact between the solution and additional surface of the vial. 
The user should be aware of the fact that Aβ1-42 in CSF can aggregate and bind to surfaces, 
particularly to glass.  
9.4 Minimum sample intake 
The minimum sample intake for which within-vial homogeneity was proven is 15 µL. For 
smaller sample intakes the user needs to verify the within-vial homogeneity. 
9.5 Use of the certified value 
The purpose of these materials is either the calibration or the quality control of methods for 
the measurement of Aβ1-42 in CSF. As any reference material, they can be used for 
establishing control charts or in validation studies. 
Comparing an analytical result with the certified value 
A result is unbiased if the combined standard uncertainty of measurement and certified value 
covers the difference between the certified value and the measurement result (see also ERM 
Application Note 1, www.erm-crm.org [16]. 
When assessing the method performance, the measured values of the CRMs are compared 
with the certified values. The procedure is summarised here: 
- Calculate the absolute difference between mean measured value and the certified 
value (∆meas). 
- Combine the measurement uncertainty (umeas) with the uncertainty of the  
certified value (uCRM): 22 CRMmeas uuu +=∆  
- Calculate the expanded uncertainty (U∆) from the combined uncertainty (u∆,) using an 
appropriate coverage factor, corresponding to a level of confidence of approximately 95 % 
- If ∆meas ≤ U∆ then no significant difference exists between the measurement result and 
the certified value, at a confidence level of approximately 95 %. 
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Annexes 
Annex A: Results of the homogeneity measurements 
 
Figure A1: Regression of the results in the analytical sequence order for (A) ERM-
DA480/IFCC, (B) ERM-DA481/IFCC and (C) ERM-DA482/IFCC as measured with a fully 
automated immunoassay. 
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Figure A2: Homogeneity data of Aβ1-42 in (A) ERM-DA480/IFCC, (B) ERM-DA481/IFCC and 
(C) ERM-DA482/IFCC as measured with a fully automated immunoassay. Shown are the 
averages per vial number and their 95 % confidence interval based on the within-group 
standard deviation as derived from a one-way ANOVA of all data grouped by vial number 
after correction of the analysis trend. 
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Figure A3: Regression of the results in the analytical sequence order for (A) ERM-
DA480/IFCC and (B) ERM-DA482/IFCC as measured by ELISA. 
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Figure A4: Homogeneity data of Aβ1-42 in (A) ERM-DA480/IFCC, (B) ERM-DA481/IFCC and 
(C) ERM-DA482/IFCC as measured by ELISA. Shown are the averages per vial number and 
their 95 % confidence interval based on the within-group standard deviation as derived from 
a one-way ANOVA of all data grouped by vial number after correction of the analysis trend. 
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Annex B: Results of the short-term stability measurements 
 
 
 
Figure B1: Isochronous short-term stability measurements of Aβ1-42 (stored at -20 °C) in A) 
ERM-DA480/IFCC, B) ERM-DA481/IFCC and C) ERM-DA482/IFCC as measured by ELISA. 
Shown are the averages per time point and their 95 % confidence interval based on the 
within-group standard deviation as derived from a one-way ANOVA of all data grouped by 
time. 
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Annex C: Results of the long-term stability measurements 
 
 
 
Figure C1: Isochronous long-term stability measurements of Aβ1-42 (stored at -70 °C) in A) 
ERM-DA480/IFCC, B) ERM-DA481/IFCC and C) ERM-DA482/IFCC as measured by ELISA. 
Shown are the averages per time point and their 95 % confidence interval based on the 
within-group standard deviation as derived from a one-way ANOVA of all data grouped by 
time. 
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Annex D: Summary of methods used in the characterisation study 
Table D1: Summary of methods used in the characterisation study. Method information is 
given as reported by laboratory 
Laboratory 
code 
CSF 
volume 
[µL] 
LC system LC mobile phase Column MS 
L01 100 ACQUITY 
UPLC (Waters) 
A-0.1 % NH4OH 
B-ACN:MeOH:TFE 
(70:25:5) 
BEH300 C18, 1.7 
µm, 2.1x150mm 
Waters 
Xevo-TQS 
L02 250 ACQUITY 
Classic UPLC 
A-0.3% NH4OH 
B-ACN:0.3% NH4OH 
(90:10) 
ACQUITY UPLC 
BEH C18 300Å, 
2.1 x150 mm 1.7 
µm PST column 
Waters 
Xevo-TQS 
L03 200 Dionex 
(Thermo 
Scientific) 
Ultimate 3000 
A-5 % ACN, 0.3 % 
NH4OH 
B-96 % ACN, 0.1 % 
NH4OH 
Dionex (Thermo 
Scientific) 
Proswift RP-4H 
1x250 
Thermo 
Scientific Q 
Exactive 
L04 200 Dionex 
(Thermo 
Scientific) 
Ultimate 3000 
A-5 % ACN, 0.075 % 
NH4OH 
B-95 % ACN, 0.025 % 
NH4OH 
Dionex (Thermo 
Scientific) 
Proswift RP-4H 
1x250 
Thermo 
Scientific Q 
Exactive 
L05 100 Three Waters 
Binary Solvent 
Manager 
(BSM) 
A-0.3 % NH4OH 
B-ACN:H2O:TFE 
(90:5:5) 
ACQUITY UPLC 
BEH300 C18, 2.1 
mm x 150 mm, 
1.7 µm, Waters 
Waters 
Xevo-TQS 
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Annex E: Results of the characterisation measurements 
 
 
 
 
 
 
Figure E1: Graph showing average Aβ1-42 concentrations in CSF in A) ERM-DA480/IFCC,  
B) ERM-DA481/IFCC and C) ERM-DA482/IFCC as measured with the reference 
measurement procedures. The bars represent the laboratory means ± 2s. The full line 
represents the mean of the means and the dotted lines represent the mean of the means ± 
2s. 
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Annex F: Commutability 
 
 
 
 
Figure F1: An example of results from commutability study for Aβ1-42 in CSF. Plotted are the 
measurement results for clinical samples (in grey) and RM samples (in black). Patient 
samples are shown as (■), ERM-DA480/IFCC as (♦), ERM-DA481/IFCC as (●) and ERM-
DA482/IFCC as (▲).  
 
Table F1: Summary of methods used in the commutability study. 
Measurement Procedure Company/Institute 
EUROIMMUN beta-amyloid (1-42) EUROIMMUN AG 
IBL Amyloid-beta (1-42) CSF ELISA IBL International GmbH 
INNOTEST® β-AMYLOID(1-42) Fujirebio Europe N.V. 
Lumipulse® G β-Amyloid(1-42) Fujirebio Europe N.V. 
V-PLEX® Aβ Peptide Panel 1 (6E10) Meso Scale Discovery, LLC. 
Elecsys β-amyloid (1-42) Roche Diagnostics GmbH 
LC-MS RMP1 University of Gothenburg 
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